iwNHL 2019 Session V: Novel Lymphoma Targets/Agents

Zanubrutinib: a highly targeted Bruton tyrosine kinase inhibitor

Andrew Zelenetz

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter